Canada markets closed

AVITA Medical, Inc. (GCR.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.28130.0000 (0.00%)
At close: 7:59PM CEST
Full screen
Previous Close0.2813
Open0.0000
Bid0.0000 x 7407500
Ask0.0000 x 5714300
Day's Range0.2813 - 0.2813
52 Week Range0.1640 - 5.6260
Volume81
Avg. Volume346
Market Cap150.034M
Beta (5Y Monthly)0.35
PE Ratio (TTM)N/A
EPS (TTM)-0.1680
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    AVITA Medical to Present at Upcoming Investor Conferences

    VALENCIA, Calif., and MELBOURNE, Australia, Nov. 16, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that its management will present at the following upcoming investor conferences: Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumPresenting on Thursday, Novembe

  • GlobeNewswire

    AVITA Medical Reports First Fiscal Quarter 2022 Financial Results

    VALENCIA, Calif. and MELBOURNE, Australia, Nov. 08, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (the “Company”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its first fiscal quarter ended September 30, 2021. First Quarter Fiscal Year 2022 Highlights Total revenue increased 39% to $7.0 million compared to $5

  • GlobeNewswire

    AVITA Medical Announces Expanded Medicare Reimbursement to Outpatient Hospital and Ambulatory Surgical Centers

    Effective January 1, 2022, a new code describes the RECELL® SystemVALENCIA, Calif. and MELBOURNE, Australia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that the Centers for Medicare & Medicaid Services (CMS) has approved AVITA Medical’s application for a Transitional Pass-